Page 335 - Read Online

Palmetun Ekbäck et al. Topical rapamycin tuberous sclerosis clinical practice

In conclusion, topical rapamycin is a valuable tool in Dermatol 2011;147:1116-7.
the treatment of angiofibromas even when treatment 8. Truchuelo T, Diaz-Ley B, Rios L, Alcantara J, Jaen P. Facial
was performed every second to third day. Erythema angiofibromas treated with topical rapamycin: an excellent choice with
and papules seem to respond in most cases, but 9. fast response. Dermatol Online J 2012;18:15.
Kaufman McNamara E, Curtis AR, Fleischer AB Jr. Successful
nodules respond less well to topical rapamycin. The treatment of angiofibromata of tuberous sclerosis complex with
treatment must be continuous. Rapamycin was not rapamycin. J Dermatolog Treat 2012;23:46-8.
detected in the blood in our patients, which is in line 10. Knopfel N, Martin-Santiago A, Bauza A, Hervas JA. Topical 0.2%
with other studies. Topical Rapamycin could also be rapamycin to treat facial angiofibromas and hypomelanotic macules in
a valuable complement after CO 2 laser in order to tuberous sclerosis. Actas Dermosifiliogr 2014;105:802-3.
maintain the improvement after the laser surgery. 11. Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama
I. A topical combination of rapamycin and tacrolimus for the treatment
of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study
Acknowledgments of nine Japanese patients with TSC of different disease severity. Br J
Authors thank Janet Holmén for revising the English. Dermatol 2011;165:912-6.
12. Foster RS, Bint LJ, Halbert AR. Topical 0.1% rapamycin for
Financial support and sponsorship angiofibromas in paediatric patients with tuberous sclerosis: a pilot
study of four patients. Australas J Dermatol 2012;53:52-6.
None. 13. Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, Ruano J, Galán-
Gutierrez M, Vélez A, Moreno-Giménez JC. Sustained clinical
Conflicts of interest effectiveness and favorable safety profile of topical sirolimus for
There are no conflicts of interest. tuberous sclerosis - associated facial angiofibroma. J Eur Acad
Dermatol Venereol 2012;26:1315-8.
14. Tanaka M, Wataya-Kaneda M, Nakamura A, Matsumoto S, Katayama
Patient consent I. First left-right comparative study of topical rapamycin vs. vehicle for
All patients and/or parents gave their informed consent. facial angiofibromas in patients with tuberous sclerosis complex. Br J
Dermatol 2013;169:1314-8.
Ethics approval 15. Park J, Yun SK, Cho YS, Song KH, Kim HU. Treatment of
angiofibromas in tuberous sclerosis complex: the effect of topical
This kind of clinical follow-up doesn’t need formal rapamycin and concomitant laser therapy. Dermatology 2014;228:37-41.
ethics approval in Sweden. 16. Tu J, Foster RS, Bint LJ, Halbert AR. Topical rapamycin for
angiofibromas in paediatric patients with tuberous sclerosis: follow up
REFERENCES of a pilot study and promising future directions. Australas J Dermatol
2014;55:63-9.
1. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. 17. Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner
Ann N Y Acad Sci 1991;615:125-7. A, Northrup H. Topical rapamycin therapy to alleviate the cutaneous
2. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance manifestations of tuberous sclerosis complex: a double-blind,
and management: recommendations of the 2012 International randomized, controlled trial to evaluate the safety and efficacy of
Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol topically applied rapamycin. Drug R D 2012;12:121-6.
2013;49:255-65. 18. Vasani RJ. Facial angiofibromas of tuberous sclerosis treated with topical
3. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet sirolimus in an Indian patient. Indian J Dermatol 2015;60:165-9.
2008;372:657-68. 19. Pynn EV, Collins J, Hunasehally PR, Hughes J. Successful topical
4. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, rapamycin treatment for facial angiofibromata in two children. Pediatr
Wüthrich RP, Serra AL. The mTOR inhibitor rapamycin significantly Dermatol 2015;32:e120-3.
improves facial angiofibroma lesions in a patient with tuberous 20. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD,
sclerosis. Br J Dermatol 2008;159:473-5. Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekberg H,
5. Haemel AK, O’Brian AL, Teng JM. Topical rapamycin: a novel Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba
approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko
2010;146:715-8. S, Watson C, Fergusson DA. Effect of sirolimus on malignancy and
6. Mutizwa MM, Berk DR, Anadkat MJ. Treatment of facial survival after kidney transplantation: systematic review and meta-
angiofibromas with topical application of oral rapamycin solution analysis of individual patient data. BMJ 2014;349:g6679.
(1mgmL(-1) ) in two patients with tuberous sclerosis. Br J Dermatol 21. Salido-Vallejo R, Ruano J, Garnacho-Saucedo G, Godoy-Gijón E, Llorca
2011;165:922-3. D, Gómez-Fernández C, Moreno-Giménez JC. Facial Angiofibroma
7. DeKlotz CM, Ogram AE, Singh S, Dronavalli S, MacGregor JL. Severity Index (FASI): reliability assessment of a new tool developed
Dramatic improvement of facial angiofibromas in tuberous sclerosis to measure severity and responsiveness to therapy in tuberous sclerosis-
with topical rapamycin: optimizing a treatment protocol. Arch associated facial angiofibroma. Clin Exp Dermatol 2014;39:888-93.

334 Plastic and Aesthetic Research ¦ Volume 3 ¦ October 25, 2016